ARVINAS, INC. - 8-K Filing
Arvinas reported first-quarter financial results for Q1 2026 with cash balances of $614.9M as of March 31, down from $685.4M in December 2025 due to operational spending and marketable securities losses. The company announced the FDA approval of its first drug, VEPPANU (vepdegestrant), for ESR1-mutated breast cancer under a collaboration with Pfizer, as well as key clinical updates across multiple pipeline programs including ARV-102 in Parkinson’s disease and ARV-6723 in immuno-oncology. Arvinas also announced the licensing of VEPPANU to Rigel Pharmaceuticals. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ARVN